Revolution Medicines (RVMD) CEO Goldsmith sells $18 million in shares
Published on Β· Source: investing.com
AI Summary
Summarized by AI from the source belowRevolution Medicines (RVMD) CEO Mark Goldsmith sold shares valued at $18 million. This sale reflects a significant transaction that may influence investor sentiment and perceptions of the company's future. The timing and volume of the sale could affect the stock's trading activity in the short term. Such insider trading activity is notable as it can signal confidence or potential shifts in strategy within the company.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
